Journal of Clinical Oncology
Articles in this Issue
Integration of advanced practice nurses and telemonitoring in the management of immune-mediated adverse events in patients with lung cancer.
e23288 Background: Lung cancer (LC) has a major impact on the healthcare system and on patients’ lives. Care management is becoming increasingly complex,...
A clinical study using AI based imaging analysis technology to continuously monitor sarcopenia and clinical prognosis in patients with esophageal cancer.
e16020 Background: In recent years, impact of sarcopenia on the prognosis of esophageal cancer has drawn attention to the esophageal cancer patients. This...
Plasma epigenomic profiling to reveal molecular correlates of response and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC).
5074 Background: The PSMA-directed radioligand therapy, 177Lu-PSMA-617, is the most recent FDA approved therapy in mCRPC. Despite prolonging progression-f...
Importance of RECIST 1.1 training program for improving performance of contract research organization (CRO) staff in solid tumor clinical trials.
e21018 Background: Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1 remains an essential part of the assessment of tumor burden in solid...
The development and validation of a simulation model–based calculation engine to support individualized physical activity prescriptions for breast cancer survivors.
10517 Background: Current cancer physical activity guidelines recommend clinicians offer individualized ‘physical activity prescriptions’ to cancer surviv...
Concordance between blinded independent central review committee and physician-assessed responses: Analyses based on a real-world external control arm in relapsed/refractory multiple myeloma using International Myeloma Working Group data.
e19521 Background: Blindedindependent central review (BICR) committees are often established for oncology trials to assessbestoverall response (BOR), whil...
Incidence and predictors of exceptional response (ExRes) in patients (pts) initiating first-line (1L) treatment for HER2-positive (HER2+) metastatic breast cancer (MBC).
e13021 Background: HER2-targeted therapies have revolutionized the treatment of HER2+ MBC; however, pt responses can be heterogeneous. ExRes in MBC, defin...
Temporal trends and determinants of palliative care utilization among hospitalized patients with acute myeloid leukemia.
e13832 Background: Patients with acute myeloid leukemia (AML) are frequently hospitalized for intensive chemotherapy and treatment-related complications a...
Breast cancer optimal care timeframes for culturally and linguistically diverse populations and First Nations People: A regional centre experience in Australia.
1587 Background: Culturally and linguistically diverse (CALD) populations and First Nations People are at-risk communities who face unique challenges in c...
Efficacy and safety of metronomic oral vinorelbine combined with PD-1 inhibitors as first-line therapy in advanced non-small-cell lung cancer in elderly patients.
8564 Background: Elderly individuals aged over 70 constitute the majority of Non-small cell lung cancer(NSCLC) patients. However, their poor general statu...
Moments of connection between clinicians and patients in oncology: A mixed-methods exploratory study of sacred moments.
e21004 Background: Sacred moments – brief periods of deep interconnectedness between clinicians and patients – have been associated with enhanced well-bei...
Long-term safety of belzutifan in von Hippel-Lindausyndrome: A single-center experience.
10605 Background: Belzutifan has improved control in Von Hippel-Lindau (VHL) syndrome, reducing the need for interventions. However, its long-term safety...
Real-world disparities in survival among stage III-IV melanoma patients in the era of immunotherapy.
e13767 Background: The CheckMate 067 and KEYNOTE-006 trials transformed melanoma care, improving survival outcomes. However, disparities in survival persi...
Identifying key molecular drivers of survival and therapeutic targets in glioblastoma through integrated transcriptomic analysis.
2080 Background: Glioblastoma multiforme (GBM) remains one of the most aggressive brain tumors, characterized by poor survival rates and limited therapeut...
Deep learning as a predictor for MammaPrint risk group from pathology slides in Chinese early-stage breast cancer.
e13670 Background: MammaPrint (MP) test has been used to evaluate the prognosis and chemotherapy benefit of hormonal receptor positive human epidermal rec...
Effect of CD73 on immune escape via tryptophan metabolic reprogramming in diffuse large B-cell lymphoma.
7068 Background: Immunotherapy is playing an increasingly important role in patients with relapsed or refractory DLBCL. Our previous studies have shown th...
First-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A nationwide, retrospective real-world study.
e20589 Background: Camrelizumab plus chemotherapy has been approved for the fist-line treatment of advanced non-squamous non-small cell lung cancer (NSCLC...
Frailty in lung cancer hospitalizations: Identifying critical predictors for improved patient outcomes.
11170 Background: Frailty is a condition primarily characterized by deficits in multiple health-related factors, which, when combined with the presence of...
Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.
3055 Background: Risk of recurrence for patients (pts) with HR+/HER2- breast cancer persists for decades. Most distant recurrences occur in the ‘late’ adj...
Association of infiltration of hematopoietic stem cells (HSC) with cell proliferation and patient survival in breast cancer.
562 Background: HSCs, also known as blood stem cells, are self-renewable cells that can develop into all types of blood cells. They are found in bone marr...
Integrated health system for resolving breast cancer screening actions: Multicenter randomized clinical study—Itaberaí randomized trial, ReBEC, RBR-39vm2nd.
1511 Background: The ITABERAÍ Project involves an intervention through training of Community Health Workers (CHW), based on evidence from clinical breast...
Chemotherapy plus anti-PD-1 or anti-PD-L1 in advanced PD-L1–negative squamous cell lung carcinoma: A systematic review and meta-analysis.
e20586 Background: Squamous cell lung carcinoma (sqNSCLC) accounts for 25-30% of all non-small cell lung cancer (NSCLC) cases and is associated with poor...
Pain in cancer survivors in the US after federal and state opioid prescribing guidelines and laws.
11028 Background: Cancer-associated pain is common among survivors and may require opioid medications for effective management. In 2016, the Centers for D...
Trends of malignant neoplasms of bone and articular cartilage across three decades.
e23508 Background: Bone and articular cartilage malignant neoplasms are rare, yet they contribute an important contribution to the overall morbidity and m...
Artificial intelligence (AI) based spatial assessment of tumor-infiltrating lymphocytes (TIL) and pathologic complete response in early HER2+ breast cancer (BC): Secondary analysis of NSABP B-41.
551 Background: Manual quantitative assessment of stromal TILs has shown promise as a biomarker in HER2+ BC. We present an AI-powered single-cell TIL asse...